Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Products under Development by Stage of Development | 8 | 1 |
| RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Products under Development by Therapy Area | 9 | 1 |
| RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Products under Development by Indication | 10 | 2 |
| RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Products under Development by Companies | 14 | 5 |
| RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Therapeutics Assessment | 19 | 4 |
| Assessment by Monotherapy/Combination Products | 19 | 1 |
| Assessment by Mechanism of Action | 20 | 1 |
| Assessment by Route of Administration | 21 | 1 |
| Assessment by Molecule Type | 22 | 1 |
| RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Companies Involved in Therapeutics Development | 23 | 8 |
| Almac Discovery Limited | 23 | 1 |
| ArQule, Inc. | 24 | 1 |
| AstraZeneca Plc | 25 | 1 |
| Bayer AG | 26 | 1 |
| Critical Outcome Technologies Inc. | 27 | 1 |
| Merck &Co., Inc. | 28 | 2 |
| Novartis AG | 30 | 1 |
| RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Drug Profiles | 31 | 26 |
| ADC-0008830 Drug Profile | 31 | 1 |
| ALM-301 Drug Profile | 32 | 1 |
| ARQ-092 Drug Profile | 33 | 3 |
| AZD-5363 Drug Profile | 36 | 3 |
| BAY-1001931 Drug Profile | 39 | 1 |
| BAY-1125976 Drug Profile | 40 | 1 |
| COTI-2 Drug Profile | 41 | 8 |
| MK-2206 Drug Profile | 49 | 3 |
| MK-2206 + selumetinib sulfate Drug Profile | 52 | 1 |
| Small Molecules to Inhibit Akt1/2 for Oncology Drug Profile | 53 | 1 |
| trametinib dimethyl sulfoxide + uprosertib Drug Profile | 54 | 2 |
| uprosertib Drug Profile | 56 | 1 |
| RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Dormant Projects | 57 | 3 |
| RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Featured News &Press Releases | 60 | 9 |
| Jun 06, 2016: Critical Outcome Activates Second Clinical Trial Site for Its COTI-2 Gynecological Cancer Study | 60 | 1 |
| May 24, 2016: Critical Outcome Receives Additional Patent Protection for Potential Transformational P53 Cancer Treatment | 60 | 1 |
| Apr 27, 2016: Critical Outcome Technologies Augments Advisory Board Drug Development Experience | 61 | 1 |
| Apr 19, 2016: Critical Outcome Commences Treatment of Second Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers | 61 | 1 |
| Feb 16, 2016: Critical Outcome Treats First Patient in Phase 1 Study of COTI-2 in Gynecologic Cancers | 62 | 1 |
| Jan 28, 2016: ArQule Provides Update on ARQ 092 | 62 | 1 |
| Dec 02, 2015: Critical Outcome Technologies Pursues Orphan Drug Designation for COTI-2 Intended to Treat Li-Fraumeni Syndrome | 63 | 1 |
| Nov 17, 2015: ArQule and the National Human Genome Research Institute of the National Institutes of Health Announce Enrollment of First Patient in the Phase 1 Proteus Syndrome Trial With ARQ 092 | 64 | 1 |
| Nov 08, 2015: BIND Presents Data on MK-2206, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | 65 | 1 |
| Oct 26, 2015: BIND Therapeutics' Presentation at Upcoming AACR-NCI-EORTC Conference Reinforce Potential of Accurin Platform to Develop Best-in-Class Therapeutics | 66 | 1 |
| Oct 15, 2015: ArQule Announces Publication of Manuscript Highlighting Activity of AKT Inhibitor ARQ 092 in Oncology | 66 | 1 |
| Sep 28, 2015: ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference | 67 | 1 |
| May 26, 2015: FDA Grants IND to Critical Outcome Technologies for COTI-2, the Company's Activator of Mutant p53 Protein | 67 | 1 |
| May 11, 2015: Critical Outcome Technologies Adds First European Patent to Growing Intellectual Property Protection for COTI-2 | 68 | 1 |
| Apr 27, 2015: Critical Outcome Technologies Files Investigational New Drug Application With the FDA for COTI-2 | 68 | 1 |
| Appendix | 69 | 2 |
| Methodology | 69 | 1 |
| Coverage | 69 | 1 |
| Secondary Research | 69 | 1 |
| Primary Research | 69 | 1 |
| Expert Panel Validation | 69 | 1 |
| Contact Us | 69 | 1 |
| Disclaimer | 70 | 1 |